The Market — Data Response Practice

Edexcel IAL Business Unit 1 (WBS11)

Stimulus

Ozempic and weight-loss drug shortages reshape the pharma market

Global demand for GLP-1 weight-loss and diabetes drugs — most notably Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound — has surged since 2023, creating one of the most visible supply–demand mismatches in the pharmaceutical sector in recent years. In the UAE, regulators approved Wegovy for prescription use in 2024, and pharmacy chains in Dubai have reported frequent stockouts through 2024–25, with pharmacy-listed prices for a one-month Wegovy supply ranging between approximately AED 1,100 and AED 1,500 depending on dosage.

The demand surge has multiple drivers. Rising obesity prevalence across the GCC — the UAE reports adult obesity at approximately 27.8% — combined with growing cultural acceptance of weight-management medication, and heavy coverage on social media platforms, has pushed demand well above prior forecasts. Novo Nordisk has publicly stated that it is expanding capacity, with new production facilities under construction in Denmark, France and the United States, but supply adjustments in biologic drug manufacturing take years rather than months. Meanwhile, compounded versions of semaglutide (the active ingredient in Ozempic) emerged as a grey-market substitute in several countries, though the UAE and Singapore have restricted their sale.

The price elasticity of demand (PED) for branded weight-loss drugs in the UAE private-pay market has been estimated at around -0.4, reflecting low substitutability and the absence of widespread insurance coverage. On the supply side, the market is highly concentrated: Novo Nordisk and Eli Lilly together account for an estimated 85–90% of the global GLP-1 market. Generic versions of semaglutide are not expected in major markets until at least 2031, when Novo Nordisk's patents begin to expire.

In Singapore, the Ministry of Health has taken a cautious stance: Wegovy is approved for obesity treatment but prescription is restricted to clinical criteria, which has limited speculative demand. In India, the drug was approved in 2025 and list prices were set substantially below UAE levels — reported at around INR 17,000–24,500 per month — reflecting Eli Lilly's tiered-pricing approach in emerging markets.

Table 1: Estimated global supply and demand, GLP-1 weight-loss drugs (2024–26 projection)

Source: Composite industry and analyst projections, 2024–25.

Questions

Question 1 (2 marks) — Using data from the stimulus, calculate the absolute price difference (in AED) between the highest-priced one-month Wegovy supply in the UAE and the lower bound of the Indian list price. Assume INR 24,500 equals approximately AED 1,080.

Question 2 (6 marks) — Analyse how supply constraints on GLP-1 drugs have affected market equilibrium in the UAE private-pay weight-loss drug market.

Question 3 (10 marks) — Discuss the implications of a PED of -0.4 for Novo Nordisk's pricing strategy on Wegovy in the UAE over the next three years.

Model Answers

Question 1 (2 marks)

Highest UAE Wegovy one-month price: AED 1,500. Indian upper list price (INR 24,500) is stated as approximately AED 1,080. Difference = 1,500 − 1,080 = AED 420. The UAE price is approximately AED 420 higher than the upper bound of the Indian list price for a one-month supply.

Examiner note: Full marks require the calculation shown and a clear currency-matched answer. A common mistake is subtracting without first converting, or mixing the INR and AED units.

Question 2 (6 marks)

Market equilibrium is the price and quantity combination at which quantity demanded equals quantity supplied. When supply is constrained, the supply curve shifts leftward (or is effectively vertical at a capacity limit), which, if demand is unchanged or rising, leads to a higher equilibrium price.

Applied to the UAE Wegovy market, demand has surged due to high obesity prevalence (approximately 27.8% adult rate) and regulatory approval in 2024, shifting the demand curve rightward. At the same time, Novo Nordisk has been capacity-constrained because biologic manufacturing cannot scale in months, and the UAE has restricted grey-market compounded alternatives — both of which keep supply inelastic. The result is that the demand and supply imbalance clears at a higher price (AED 1,100–1,500 per month for Wegovy) and frequent stockouts indicate that even at those prices, quantity demanded exceeds quantity supplied at some points.

The chain of reasoning is: rising demand plus inelastic supply produces a shortage; pharmacies ration by stockouts rather than price alone; price drifts upward within the AED 1,100–1,500 band as pharmacies facing scarcity capture some of the consumer surplus; and the shortage will persist until capacity catches up — projected to narrow only by 2026 as global supply rises to roughly 330 million patient-months against demand of approximately 34 million patients.

Examiner note: Level 3 (5–6) answers distinguish clearly between a demand shift and a supply constraint, quote the AED 1,100–1,500 price band, and reference the 2026 narrowing projection. Level 2 (3–4) answers describe higher prices without tying them to specific curve movements. A common mistake is treating the shortage as a one-off rather than a structural capacity issue.

Question 3 (10 marks)

Price elasticity of demand (PED) measures how responsive quantity demanded is to a change in price. A PED of -0.4 for Wegovy in the UAE private-pay market indicates inelastic demand: a 10% price rise would cause a less-than-proportionate fall of roughly 4% in quantity demanded. For Novo Nordisk, this has significant implications for pricing strategy over the next three years.

First, inelastic demand creates a strong incentive to maintain high prices. Because quantity demanded does not fall by much when price rises, total revenue increases with a price rise. This is consistent with Novo Nordisk's premium AED 1,100–1,500 pricing of Wegovy in the UAE, against a tiered-lower price of roughly AED 750–1,080 equivalent in India. In a supply-constrained market — where Novo Nordisk and Eli Lilly hold 85–90% combined market share and generic entry is blocked until patent expiry around 2031 — the low substitutability underpinning the -0.4 PED is likely to persist. The strategic implication is that Novo Nordisk can extract high margins in the UAE through at least 2028–29.

Second, the absence of widespread insurance coverage in the UAE private-pay market means the full cost falls on the consumer, which tests willingness to pay. Even with inelastic demand, there is a ceiling above which the patient population contracts sharply — particularly because the clinical category can be delayed rather than abandoned if prices rise too far. Inelastic demand does not mean unlimited pricing power.

However, there are counterarguments to a purely high-price strategy. First, regulatory risk is real. The UAE Ministry of Health could designate Wegovy as a priority drug and impose price-control measures if stockouts and affordability become politically visible, particularly given public-health costs associated with obesity. Similar pressure has emerged in other markets, such as Singapore, which has restricted prescription to strict clinical criteria, reducing speculative demand and limiting price discovery at the top end.

Second, competitive dynamics can shift. Eli Lilly's Mounjaro and Zepbound are direct substitutes, and cross-price elasticity of demand between branded GLP-1 drugs is likely to be positive. If Eli Lilly prices more aggressively — as it has done in India with INR 17,000–24,500 list prices — Novo Nordisk faces pressure to match, particularly for price-sensitive segments of the private-pay market.

Third, reputational and long-term considerations matter. Charging a high multiple of the Indian price (AED 1,500 vs AED 1,080 upper bound in India) for the same drug creates reputational exposure and may lead to parallel imports or cross-border prescription tourism from patients in the region.

Fourth, approaching patent expiry in 2031 means that Novo Nordisk should consider how to transition from price-maximising to share-maximising strategy. Building customer loyalty, prescriber relationships and brand strength now may matter more than extracting maximum price, because once generics enter, PED will rise sharply.

In evaluation, the -0.4 PED supports premium pricing in the near term, but is not a licence to maximise price without constraint. Over the next three years, Novo Nordisk's pricing should reflect a balance between short-run revenue extraction and longer-run considerations — regulatory risk, competitive entry from Eli Lilly, and brand positioning ahead of patent expiry. A sensible conclusion is that the -0.4 PED justifies maintaining the AED 1,100–1,500 band in the short term but should be reviewed as regulatory, competitive and capacity conditions evolve.

Examiner note: Level 4 (9–10) answers explicitly quantify using the PED (-0.4), quote the AED band and Indian comparator, and evaluate using regulatory risk, competitive dynamics, and time-horizon. Level 3 answers explain inelastic pricing in general without applying to Wegovy specifically. A common mistake is claiming inelastic demand means unlimited price rises, ignoring the risk of regulator intervention.

Common Mistakes

• Confusing a movement along a demand curve with a shift of the demand curve. Fix: a higher price with unchanged preferences is a movement; a change in tastes, income or awareness is a shift.
• Treating PED of -0.4 as an excuse to raise prices indefinitely. Fix: inelastic demand raises revenue for moderate price rises, but extreme rises change consumer behaviour (substitutes, delay) and trigger regulatory risk.
• Failing to use both currency values correctly. Fix: always convert to the same currency before calculating a price gap or percentage.

Diagram Reference

This data-response uses the following diagram from the Revvy Learn diagram library:

• supply-demand-equilibrium.svg — used here to show a rightward demand shift against inelastic supply, producing a higher price and shortage at the original price

(Two additional diagrams are on the v2 backlog: an inelastic-demand curve with revenue rectangle showing the impact of a price rise on total revenue, and a tiered-pricing comparison diagram illustrating cross-country price discrimination.)